Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …

Cases with pituitary adenoma comprise 10–25% of intracranial neoplasm, being the third
most common intracranial tumor, most of the adenomas are considered to be benign. About …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

The tumour microenvironment (TME) includes a variety of non-neoplastic cells and non-
cellular elements such as cytokines, growth factors and enzymes surrounding tumour cells …

Propranolol, a lipophilic nonselective β-blocker, has recently been reported to be the
treatment of choice for select types of infantile hemangiomas (IHs). Atenolol is a hydrophilic …

Recently, advances in molecular biology and bioinformatics have allowed a more thorough
understanding of tumorigenesis in aggressive PitNETs (pituitary neuroendocrine tumors) …

Acute kidney injury (AKI) is a frequent complication in hospitalised patients and is diagnosed
by urinary output and serum creatinine. Serum creatinine is an indirect marker for renal …

Pituitary adenomas (PAs) are mostly benign endocrine tumors that can be treated by
resection or medication. However, up to 10% of PAs show an aggressive behavior with …

Object: This study aimed to explore the relationship between the aggressiveness and
immune cell infiltration in pituitary adenoma (PA) and to provide the basis for immuno …

To explore the prognostic related factors and mechanisms of gastric cancer (GC), we
performed the systematic analysis with integrated bioinformatics tools based on multiple on …